Helge G. Bischoff
Heidelberg, BW, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 50 publications
Chemoimmunotherapy Versus Chemotherapy for Extensive-Stage Small Cell Lung Cancer in the Real-World Setting: Retrospective Study of 904 Patients.
Journal: Clinical lung cancer
Published: April 05, 2026
Neoadjuvant Atezolizumab and Chemotherapy for Non-Squamous Non-Small Cell Lung Cancer: Efficacy and Safety Results of an Open-Label, Single-Arm, Phase II Trial.
Journal: International journal of cancer
Published: January 17, 2026
Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: results of the NEOMUN trial.
Journal: Journal for immunotherapy of cancer
Published: July 07, 2025
First-line nivolumab plus ipilimumab in pleural mesothelioma: Efficacy and safety data from the real-world MesoNet study.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: April 13, 2025
Durvalumab after sequential chemoradiotherapy in unresectable stage III non-small-cell lung cancer-final analysis from the phase II PACIFIC-6 trial.
Journal: ESMO open
Published: November 18, 2024
Impact of the number of involved lymph node zones on survival in stage IIIA-N2 lung adeno and squamous cell carcinoma.
Journal: Interdisciplinary cardiovascular and thoracic surgery
Published: October 08, 2024
Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer.
Journal: British journal of cancer
Published: March 31, 2024
Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer-final results of the EUCROSS trial.
Journal: ESMO open
Published: August 15, 2023
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 22, 2023
Lorlatinib and compound mutations in ALK+ large-cell neuroendocrine lung carcinoma: a case report.
Journal: Cold Spring Harbor molecular case studies
Published: July 11, 2022
Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: May 26, 2022
Last Updated: 09/26/2026